Anaptysbio Stock Investor Sentiment

ANAB Stock  USD 38.48  0.95  2.53%   
About 59% of AnaptysBio's investor base is looking to short. The analysis of the overall investor sentiment regarding AnaptysBio suggests that many traders are alarmed. The current market sentiment, together with AnaptysBio's historical and current headlines, can help investors time the market. In addition, many technical investors use AnaptysBio stock news signals to limit their universe of possible portfolio assets.
  

AnaptysBio Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards AnaptysBio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
few days ago at gurufocus.com         
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc
Gurufocus Stories at Macroaxis
few days ago at www.macroaxis.com         
Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3
Macroaxis News
six days ago at www.macroaxis.com         
Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 1300 shares by Orwin John A of AnaptysBio subject to Rule 16b-3
Macroaxis News
over a week ago at www.macroaxis.com         
Disposition of 6000 shares by Dennis Mulroy of AnaptysBio subject to Rule 16b-3
Macroaxis News
over two weeks ago at news.google.com         
AnaptysBio, Inc. Given Consensus Recommendation of Moderate Buy by Brokerages - MarketBeat
Google News at Macroaxis
over three weeks ago at finance.yahoo.com         
Anaptys Announces Participation in September Investor Conferences
Yahoo News
over a month ago at fool.com         
Why AnaptysBio Was Such a Healthy Stock This Week
fool News
over a month ago at insidermonkey.com         
Hedge Fund and Insider Trading News Carl Icahn, Ken Griffin, Warren Buffett, Engaged Capital, Elliot...
insidermonkey News
over a month ago at news.google.com         
AnaptysBio, Inc. Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
AnaptysBio, Inc. Short Interest Up 9.3 percent in July - MarketBeat
Google News at Macroaxis
over a month ago at news.google.com         
AnaptysBio Reaches New 12-Month High at 41.11 - Defense World
Google News at Macroaxis
over a month ago at news.google.com         
AnaptysBio Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha
Google News at Macroaxis
over a month ago at seekingalpha.com         
AnaptysBio prices 100M equity offering
seekingalpha News
over a month ago at investors.com         
Acquisition by Ecor1 Capital, Llc of 273972 shares of AnaptysBio at 36.5 subject to Rule 16b-3
Investors Business Daily at Macroaxis
Far too much social signal, news, headlines, and media speculation about AnaptysBio that are available to investors today. That information is available publicly through AnaptysBio media outlets and privately through word of mouth or via AnaptysBio internal channels. However, regardless of the origin, that massive amount of AnaptysBio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of AnaptysBio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AnaptysBio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AnaptysBio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AnaptysBio alpha.

AnaptysBio Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
AnaptysBio, Inc. Earnings Expected to Grow What to Know Ahead of Q4 Release - Yahoo Singapore News
06/27/2024
2
Allspring Global Investments Holdings LLC Purchases Shares of 1,688 AnaptysBio, Inc. - Defense World
07/24/2024
3
Illumina Expected to Beat Earnings Estimates Can the Stock Move Higher
07/30/2024
4
Despite currently being unprofitable, AnaptysBio has delivered a 78 percent return to shareholders over 1 year
08/02/2024
5
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
08/05/2024
6
Acquisition by Ecor1 Capital, Llc of 273972 shares of AnaptysBio at 36.5 subject to Rule 16b-3
08/14/2024
7
AnaptysBio Top-Line AD Data End Of 2024 Could Be Turning Point - Seeking Alpha
08/15/2024
8
Anaptys Announces Participation in September Investor Conferences
08/29/2024
9
Disposition of 1300 shares by Orwin John A of AnaptysBio subject to Rule 16b-3
09/13/2024
10
Disposition of 10000 shares by Dennis Mulroy of AnaptysBio at 40.13 subject to Rule 16b-3
09/16/2024
11
Disposition of 3780 shares by Eric Loumeau of AnaptysBio at 38.4103 subject to Rule 16b-3
09/17/2024
12
TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Singular Genomics Systems Inc
09/18/2024

Complementary Tools for AnaptysBio Stock analysis

When running AnaptysBio's price analysis, check to measure AnaptysBio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AnaptysBio is operating at the current time. Most of AnaptysBio's value examination focuses on studying past and present price action to predict the probability of AnaptysBio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AnaptysBio's price. Additionally, you may evaluate how the addition of AnaptysBio to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Commodity Directory
Find actively traded commodities issued by global exchanges
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios